Announcement Regarding the Inclusion of its Innovative Drug HSK31679 Tablets in the Breakthrough Therapy Program
March 13, 2026
Source: drugdu
28
March 12 - Harscon Pharmaceutical...The company announced that on March 12, 2026, it learned that HSK31679 tablets were officially included in the "Breakthrough Therapy List" by the Center for Drug Evaluation (CDE) of the National Medical Products Administration, making it the first THR-β agonist to be included in the Breakthrough Therapy List in China. Currently, no drugs are approved in China for the treatment of MASH (non-alcoholic steatohepatitis). The inclusion of HSK31679 tablets in the "Breakthrough Therapy List" will greatly promote the research and development of new drugs in this field and bring new hope for the treatment of MASH patients in my country.
https://finance.eastmoney.com/a/202603123670377648.html
Copyright©2026 Ddu. All rights reserved.
Read more on
- Fangda Pharma helps Jiminke’s Class 1 innovative drug, Jilemei®, obtain market approval. March 13, 2026
- Dexamethasone API Marketing Application Approved March 13, 2026
- China’s first innovative drug prescription based on precise postoperative assessment for thyroid cancer March 13, 2026
- The launch meeting for the research project on innovative chemical drugs for Alzheimer’s disease was held. March 13, 2026
- SHR-9803 for Injection Approved for Clinical Trials March 12, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
